JEOL Ltd. (President Gon-emon Kurihara) is pleased to announce a new brand of the in-vitro clinical chemistry analyzer, the BioMajesty™ ZERO series, targeting its market launch in April 2016 in Japan. The development of JCA-ZS050, the first analyzer of the series, has just been completed.

Product development background

JCA-ZS050 is a clinical chemistry analyzer that measures components of blood and urine, such as blood sugar level and cholesterol which have gained significant recognition worldwide as the human health index. JEOL Ltd. has distributed BioMajesty™ series since the development of JCA-BM12 in 1996 and steadily expanding the market share thanks to the high reputation from the commercial laboratories and hospitals for the performance reliability and our unique technologies of the micro-volume measurement and high throughput.
JCA-ZS050 from the BioMajesty™ ZERO series is a resolution to our customers' ever-growing needs in the medical finance, expansion of pre-diagnosis examination and increasing volume of tasks for laboratory technicians as a part of the medical team. It offers higher cost performance, utilizing even smaller reagent volumes, improved system operation and simplified customer maintenance.

Main Features
  1. Sample-to-Sample Carryover Avoidance and Superb Accuracy
    JCA-ZS050 incorporates a newly developed wash mechanism and software for sample-to-sample carryover avoidance. It also achieves the excellent data accuracy as our legacy BioMajesty™ series do, thanks to the independent sample dilution unit and the newly developed smaller cuvettes, realizing the micro-volume measurement with the minimum 40μL reaction sample volume.
  2. Extensive Improvements in Usability
    JCA-ZS050 offers significantly improved usability for our users with the new, intuitive system operation windows and much simplified daily maintenance.
  3. High Throughput
    JCA-ZS050 boasts the maximum 1,800 tests/hour with the clinical chemistry tests 1,200 tests/hour and the ISE tests 600 tests/hour. (*ISE unit is optional.)
  4. Integration with Immunoassay Analyzer
    JCA-ZS050 can be integrated with Lumipulse® L2400, an automatic Chemiluminescent Enzyme Immunoassay analyzer by FUJIREBIO INC. (President & CEO Takeshi Koyama, Corporate headquarter: Shinjuku, Tokyo, Japan), offering the users a great opportunity to run a wide range of chemistry and immunoassay tests on one platform.
    3,000 BioMajesty™ instruments and 1,300 Lumipulse® instruments have been placed in many medical institutions in Japan since their introduction to the market. The integration of JEOL's clinical chemistry analyzer and FUJIREBIO's immunoassay analyzer will provide one of the finest solutions to satisfy the wide-ranged customer needs as well as to streamline the everyday workflow in the labs.
Main Specifications
Throughput Chemistry tests: Max. 1,200 tests/hour
ISE tests (optional): Max. 600 tests/hour
Max. no of tests for system registration 103 tests (with ISE tests)
100 tests (without ISE tests)
Measurement methods Photometric, Reaction Rate Assay, 2 Point Rate Assay, Immunoassay and ISE* (*optional)
Dimensions 1,470 mm (W) × 914 mm (D) × 1,449 mm (H)
Weight 550 kg
JEOL Ltd.

JEOL is a world leader in electron optical equipment and instrumentation for high-end scientific and industrial research and development. Core product groups include electron microscopes (SEMs and TEMs), instruments for the semiconductor industry (electron beam lithography and a series of defect review and inspection tools), and analytical instruments including mass spectrometers, NMRs and ESRs.

For more information about JEOL Ltd. or any JEOL products, visit www.jeol.com.

distributed by